ADMA BIOLOGICS, INC. — Director's Dealing 2021

Mar 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADMA BIOLOGICS, INC. (ADMA)
CIK: 0001368514
Period of Report: 2021-02-25

Reporting Person: LENZ BRIAN (EVP, CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-25	Common Stock	A	63936	—	Acquired	140078	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-25	Employee Stock Option (right to buy)	$2.35	A	139000	Acquired	2031-02-25	Common Stock (139000)	Direct

Footnotes

F1: These shares represent restricted stock units ("RSUs"). Of these RSUs, 55,000 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting.

F2: Includes (i) 63,936 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 40,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (iii) 36,142 shares of common stock owned by the reporting person.

F3: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.